Mallinckrodt (NYSE:MNK) shares are trading higher on Wednesday.
The company announced it received clearance from Health Canada to start on a pilot trial of high dose inhaled nitric oxide therapy for coronavirus infection and associated lung complications.
Mallinckrodt is a manufacturer of specialty pharmaceuticals, generic drugs and imaging agents.
Mallinckrodt's stock was trading up 16% to $2.30 per share in Wednesday’s pre-market session. The stock has a 52-week high of $23.90 and a 52-week low of $1.
Related Links:
Mallinckrodt Plummets On Report Of Possible Generics Business Bankruptcy
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
